Profound Medical Corp. (TSE:PRN - Free Report) - Research analysts at Raymond James lifted their FY2024 earnings per share estimates for shares of Profound Medical in a note issued to investors on Tuesday, February 18th. Raymond James analyst M. Freeman now forecasts that the company will post earnings per share of ($1.68) for the year, up from their prior estimate of ($1.79). Raymond James currently has a "Strong-Buy" rating on the stock. The consensus estimate for Profound Medical's current full-year earnings is ($1.90) per share. Raymond James also issued estimates for Profound Medical's Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.48) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($0.24) EPS and FY2028 earnings at $1.62 EPS.
Profound Medical Price Performance
Shares of PRN traded up C$0.09 during trading hours on Thursday, reaching C$10.60. 10,635 shares of the company's stock traded hands, compared to its average volume of 6,813. The stock has a market cap of C$223.36 million, a PE ratio of -5.50 and a beta of 0.81. The company has a current ratio of 6.12, a quick ratio of 14.98 and a debt-to-equity ratio of 20.05. The firm's 50 day simple moving average is C$10.03 and its 200-day simple moving average is C$10.83. Profound Medical has a 12 month low of C$7.90 and a 12 month high of C$15.75.
Insider Activity
In other news, Director Arun Menawat Dr. bought 20,000 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The stock was bought at an average price of C$10.65 per share, for a total transaction of C$213,000.00. Also, Senior Officer Thomas Michael Tamberrino bought 13,333 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The stock was purchased at an average price of C$10.65 per share, with a total value of C$141,996.45. Corporate insiders own 8.62% of the company's stock.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Featured Articles
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
